title: Triple therapy: boon or bane for high-risk CV patients?
abstract: The combination of 2 antiplatelet agents and warfarin may be beneficial to a select group of patients, but its use remains controversial. Here's why.
authors.affiliation: Auburn University Harrison School of Pharmacy, University of Alabama Birmingham School of Medicine-Huntsville, AL 35801, USA. mccrahl@auburn.edu
authors.forename: Haley M
authors.initials: HM
authors.lastname: Phillippe
authors.forename: Sharon R
authors.initials: SR
authors.lastname: Baty
authors.forename: Candace B
authors.initials: CB
authors.lastname: Griffith
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D006801:Humans; D018579:Patient Selection; D010879:Piperazines / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D013876:Thiophenes; D014859:Warfarin; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine; D001241:Aspirin